High Levels of Chronic Immune Activation in the T-cell Compartments of Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1 and on Highly Active Antiretroviral Therapy Are Reverted by Alpha Interferon and Ribavirin...

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2009 Aug 28

PMID 19710147

Citations 68

Authors

Veronica D Gonzalez

Karolin Falconer

Kim G Blom

Olle Reichard

Birgitte Morn

Alex Lund Laursen

Nina Weis

Annette Alaeus

Johan K Sandberg

Affiliations

Soon will be listed here.

Abstract

Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.

Citing Articles

Natural Resistance to HIV Infection: Role of Immune Activation.

Naranjo-Covo M, Rincon-Tabares D, Florez-Alvarez L, Hernandez J, Zapata-Builes W Immun Inflamm Dis. 2025; 13(2):e70138.

PMID: 39998960 PMC: 11854356. DOI: 10.1002/iid3.70138.

TB and HIV induced immunosenescence: where do vaccines play a role?.

Singh M, Patel B, Seo M, Ahn P, Wais N, Shen H Front Aging. 2024; 5:1385963.

PMID: 38903242 PMC: 11188299. DOI: 10.3389/fragi.2024.1385963.

Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation.

Gandhi M, Nguyen K, Lake J, Liao D, Khodabakhshian A, Guerrero M AIDS. 2023; 38(3):317-327.

PMID: 37788081 PMC: 10841736. DOI: 10.1097/QAD.0000000000003739.

CD38: an ecto-enzyme with functional diversity in T cells.

Ghosh A, Khanam A, Ray K, Mathur P, Subramanian A, Poonia B Front Immunol. 2023; 14:1146791.

PMID: 37180151 PMC: 10172466. DOI: 10.3389/fimmu.2023.1146791.

HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers.

Proulx J, Ghaly M, Park I, Borgmann K Biomedicines. 2022; 10(4).

PMID: 35453518 PMC: 9024568. DOI: 10.3390/biomedicines10040768.

References

Merchante N, Giron-Gonzalez J, Gonzalez-Serrano M, Torre-Cisneros J, Garcia-Garcia J, Arizcorreta A . Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS. 2005; 20(1):49-57. DOI: 10.1097/01.aids.0000198087.47454.e1. View

Kovacs A, Al-Harthi L, Christensen S, Mack W, Cohen M, Landay A . CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis. 2008; 197(10):1402-7. PMC: 2443164. DOI: 10.1086/587696. View

Kim A, Lauer G, Ouchi K, Addo M, Lucas M, Schulze Zur Wiesch J . The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood. 2004; 105(3):1170-8. DOI: 10.1182/blood-2004-06-2336. View

Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H . Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356(9244):1800-5. DOI: 10.1016/s0140-6736(00)03232-3. View

Sulkowski M, Moore R, Mehta S, Chaisson R, Thomas D . Hepatitis C and progression of HIV disease. JAMA. 2002; 288(2):199-206. DOI: 10.1001/jama.288.2.199. View

Giorgi J, Hultin L, McKeating J, Johnson T, Owens B, Jacobson L . Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999; 179(4):859-70. DOI: 10.1086/314660. View

Harcourt G, Gomperts E, Donfield S, Klenerman P . Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut. 2006; 55(10):1484-7. PMC: 1629042. DOI: 10.1136/gut.2005.083758. View

Daar E, Lynn H, Donfield S, Gomperts E, OBrien S, Hilgartner M . Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis. 2001; 183(4):589-95. DOI: 10.1086/318539. View

Lempicki R, Polis M, Yang J, Mclaughlin M, Koratich C, Huang D . Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis. 2006; 193(8):1172-7. DOI: 10.1086/501365. View

10.

Bjorkstrom N, Gonzalez V, Malmberg K, Falconer K, Alaeus A, Nowak G . Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J Immunol. 2008; 181(6):4219-28. DOI: 10.4049/jimmunol.181.6.4219. View

11.

Piroth L, Grappin M, Cuzin L, Mouton Y, Bouchard O, Raffi F . Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hepat. 2000; 7(4):302-8. DOI: 10.1046/j.1365-2893.2000.00227.x. View

12.

Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R . Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001; 32(3):492-7. DOI: 10.1086/318501. View

13.

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

14.

Koziel M, Peters M . Viral hepatitis in HIV infection. N Engl J Med. 2007; 356(14):1445-54. PMC: 4144044. DOI: 10.1056/NEJMra065142. View

15.

Gonzalez V, Bjorkstrom N, Malmberg K, Moll M, Kuylenstierna C, Michaelsson J . Application of nine-color flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets. J Immunol Methods. 2007; 330(1-2):64-74. PMC: 2268636. DOI: 10.1016/j.jim.2007.10.020. View

16.

Mandl J, Barry A, Vanderford T, Kozyr N, Chavan R, Klucking S . Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 2008; 14(10):1077-87. DOI: 10.1038/nm.1871. View

17.

Deeks S, Kitchen C, Liu L, Guo H, Gascon R, Narvaez A . Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004; 104(4):942-7. DOI: 10.1182/blood-2003-09-3333. View

18.

Sherman K, Rouster S, Chung R, Rajicic N . Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002; 34(6):831-7. DOI: 10.1086/339042. View

19.

De Rosa F, Audagnotto S, Bargiacchi O, Garazzino S, Aguilar Marucco D, Veronese L . Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient. J Infect. 2006; 53(5):e215-8. DOI: 10.1016/j.jinf.2006.01.023. View

20.

Balagopal A, Philp F, Astemborski J, Block T, Mehta A, Long R . Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008; 135(1):226-33. PMC: 2644903. DOI: 10.1053/j.gastro.2008.03.022. View